Investigation of the association of estrogen-derived protien adducts with predictive biomarkers of breast cancer

• Main Authors: Wun-Bin Wu, 吳文斌
• Other Authors: 林伯雄
• Format: Others
• Language: zh-TW
• Published: 2017
• Online Access: http://ndltd.ncl.edu.tw/handle/02330608417012805753

碩士 === 國立中興大學 === 環境工程學系所 === 105 === The aims of this study were to investigate whether the background levels of 17β-estradiol (E2)-derived quinone protein adducts in human hemoglobin (Hb) associate with the breast cancer risk factors and indicaters of diagnosis and treatment for breast cancer, including Age, BMI, status of disease stage, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) in Taiwanese women with breast cancer. Results from the analysis indicated that levels of Hb adducts of estrogen quinones, including E2-2,3-Q-4-S-Hb and E2-3,4-Q-2-S-Hb were detected in subjects (n=30) with mean (standard deviation) levels at 365 (193) and 776 (534) pmole/g, respectively. This finding is in consistent with our previous investigation in the measurement of these adducts in breast cancer patients, suggesting that Hb adducts of estrogen quinones are highly specific to breast cancer risk. Combined our previous investigation (n=143) with current study (n=30), we compared levels of these adducts with risk factors of breast cancer, diagnosis and treatment indicators for breast cancer patients, including age, body mass index, ER(+)/(-), PR(+)/(-), HER2(+)/(-). Results indicated that levels of E2-2,3-Q-4-S-Hb and E2-3,4-Q-2-S-Hb did not correlate with the status of these indicators. Additionally, levels of these adducts are comparable as distinguished by disease stage. Levels of Hb adducts of estrogen quinones in benign tumor patients were similar to those of in malignant tumor patients. Overall, this evidence suggests that hemoglobin adducts of estrogen quinones may serve as a screening biomarkers for subjects at high risk of developing breast cancer.